Skip to main content

Table 1 Baseline characteristics at randomization

From: Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial

 

Vilobelimab + BSC

BSC

Characteristics

 n

8

9

 Sex = male (%)

5 (62.5)

6 (66.7)

 Age

61.5 [51.0, 61.5]

61.0 [55.0, 68.0]

 Body-mass index

27.3 [24.4, 31.1]

29.0 [25.8, 30.6]

 Race (%)

  Asian

4 (50.0)

2 (22.2)

  Black or African American

2 (25.0)

2 (22.2)

  White

2 (25.0)

5 (55.6)

 Days since onset of COVID-19 symptoms

11.00 [7.5, 11.5]

13.0 [12.0, 14.0]

Medical history

 Asthma or other chronic pulmonary disease

2 (25.0)

0 (0.0)

 Cardiac disorders

3 (37.5)

1 (11.1)

 Diabetes mellitus type 2

3 (37.5)

2 (22.2)

 Hypertension

4 (50.0)

2 (22.2)

 Obesity

2 (25.0)

4 (44.4)

 Number of comorbidities

2.5 [1.0, 3.3]

2.0 [1.0, 2.0]

 Patients with relevant comorbidities

7 (87.5)

5 (55.6)

Disease severity

 Intubated at randomization

6 (75.0)

8 (88.9)

 On ICU at randomization

6 (75.0)

8 (88.9)

 qSOFA

1.0 [0.8, 1.3]

1.0 [1.0, 2.0]

 MEWS

3.5 [2.0, 5.3]

4.0 [4.0, 6.0]

Previous medication

 Antibiotics

8 (100.0)

7 (77.8)

 Chloroquine

1 (12.5)

2 (22.2)

 Remdesivir

0 (0.0)

0 (0.0)

 Steroids

2 (25.0)

1 (11.1)

  1. BSC best supportive care, MEWS Modified Early Warning Score, qSOFA quick Sequential Organ Failure Assessment